Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Lawmakers concur with Senate amendment delaying outpatient drug-price cap in H.266
Summary
Legislators agreed to a Senate amendment to H.266 that removes a temporary mid-2025 cap and leaves a 20% average-sales-price limit for outpatient-administered drugs effective Jan. 1, 2026, while keeping protections for critical access hospitals and the Green Mountain Care Board appeal process.
Legislators voted to concur with a Senate amendment to H.266 that strikes a temporary mid-2025 cap and leaves in place a limitation on outpatient-administered prescription drug charges tied to 20% of the drugs' average sales price (ASP) effective Jan. 1, 2026, while preserving carve-outs for critical access hospitals and an appeal path to the Green Mountain Care Board.
The change removes a provision that would have required a lower 30% ASP cap for certain higher-priced drugs from July 1 through Dec. 31, 2025, and instead delays the start of the outpatient-drug cap until Jan. 1, 2026. Jen Harvey, counsel in the Office of Legislative Council, summarized the amendment on the floor: "the Senate concurred in the House in your proposal of amendment on H 2 66 ... striking out section 5" and described the effect as leaving the limitation in place with a Jan. 1, 2026, effective date.
Why it matters: The change affects hospitals' charging for outpatient-administered…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
